Skip to main content

Table 4 Difference in sPSA detection rate due to previous endocrine therapy (n = 58)

From: Clinical significance of serum PSA in breast cancer patients

 

n

sPSA positive (%)

sPSA negative (%)

p value

Aromatase inhibitor resistance

0.1389

 Yes

37

16 (43.2)

21 (56.8)

 

 No

21

5 (23.8)

16 (76.2)

SERM resistance

0.4584

 Yes

23

7 (30.4)

16 (69.6)

 

 No

35

14 (40.0)

21 (60.0)

SERD resistance

0.2643

 Yes

12

6 (50.0)

6 (50.0)

 

 No

46

15 (32.6)

31 (67.4)